The MedicalXpress report on the Lancet series led by Jennifer Lees highlights 30-50% undiagnosis rates for chronic kidney disease (CKD) in high-income settings, with higher figures elsewhere, but underplays the direct mortality linkage and screening economics. This Lancet collection relies on observational global burden estimates rather than RCTs, drawing from aggregated registry data with sample sizes in the millions yet limited by selection bias and inconsistent proteinuria measurement protocols. A key omission is the absence of quantified progression modeling: observational cohorts like the CKD Prognosis Consortium (n>1.5M, predominantly high-income) show albuminuria testing reduces end-stage kidney disease incidence by 20-30% when deployed early, yet primary care integration remains negligible. Disparities data reveal non-white women face compounded risks due to lower eGFR referral thresholds, echoing patterns in hypertension studies where sex-based diagnostic delays compound cardiovascular mortality. Economic projections from Kidney Research UK (£13.9B UK burden by 2033) connect directly to missed opportunities in SGLT2 inhibitor deployment, proven in RCTs like EMPA-KIDNEY (n=6609) to slow progression, but ineffective without upstream detection. The series correctly flags urine albumin-to-creatinine ratio as low-cost, yet ignores conflicts in guideline bodies favoring specialist-led models over population screening, perpetuating the ninth-leading-cause status without mortality attribution modeling.